GemPharmatech has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.
Through the non-exclusive agreement, researchers at MSK will have access to GemPharmatech's extensive preclinical service capabilities and resources, utilising the NeoMab platform.
The platform is a next-generation transgenic mouse model designed for rapid, efficient discovery of fully human therapeutic antibodies.
The collaboration will help scientists at MSK who are already tapping a wide range of leading-edge preclinical resources to further accelerate the development of fully human therapeutic antibodies against high-value targets and address urgent, unmet needs in cancer treatment.
"Our mission has always been to enable transformative biomedical research through innovative mouse models and technologies," said Dr Xiang Gao, founder of GemPharmatech.
"Collaborating with MSK on antibody discovery represents a powerful opportunity to combine scientific excellence with cutting-edge mouse models such as NeoMab."
"Together, we can accelerate the development of novel therapeutics that address some of the most urgent challenges in cancer treatment."
Part of the world's largest library of genetically engineered mouse models (GEMMs), the immunoglobulin gene-humanised mouse model NeoMab carries the full variable gene repertoire of human heavy and kappa light chains and regulatory elements, in a BALB/c background.
This innovative design enables the rapid generation of diverse, high-affinity, fully human antibodies without the need for time-consuming sequence humanisation steps.
By skipping this process, the collaboration aims to shorten antibody development timelines and reduce immunogenicity risks.
"This collaboration underscores our mission to provide the global research community with advanced platforms to accelerate innovations in drug discovery," said Dr Brandy Wilkinson, CEO of GemPharmatech.
"We are excited to be supporting MSK's pioneering work in oncology research with the NeoMab platform."
"It is an honour to contribute to their scientific mission and to help advance antibody programmes with the potential to transform therapies and improve patient outcomes worldwide."